1. International Collaboration in FP7 Health Research
Dr. Indridi Benediktsson
Directorate Health
Horizontal Aspects and Coordination

2. Reminder: ALL RESEARCH TOPICS WERE OPEN FOR 3rd COUNTRY PARTICIPANTS
Outcome of FP6
Reminder: ALL RESEARCH TOPICS WERE OPEN FOR 3rd COUNTRY PARTICIPANTS
At least 3 organizations from EU and/or associated states
In addition, “third country” participants were welcome
Partners from the INCO target countries, could receive funding

4. Outcome of FP6
€ 2.4 billion for health research; 604 projects over the 4 years
Average success rate: 25.4%
Total number of participants: 7,426
Project type
number
av. EC contribution
partners
Integrated Projects
119
€ 10.0m 21
Networks of Excellence 40
€ 9.3m 30
STRePs
322
€ 2.2m 8
Coordination Actions 25
€ 1.1m 19
Specific Support Actions 98
€ 0.4m 6

5. 3rd countries’ participation in FP6 Health Research
Number of 3rd country participants in Health projects
Number of participants (Top Ten)
In total: 245 participants from 51 third countries

6. Timeframe for FP7 projects
Results from FP7 projects in use
Projects resulting from FP7 calls operating
Official duration of FP
2012
2006
2007
2014
2008
2009
2010
2015
2011
2013
2016
2017
2018
2019
2020
2021
First calls
First projects start
Last projects start
Last projects end

7. Cooperation – Collaborative Research
Nine themes
Health
Food, agriculture, fisheries and biotechnology
Information and communication technologies
Nanosciences, nanotechnologies, materials and new production technologies
Energy
Environment (including climate change)
Transport (including aeronautics)
Socio-economic sciences and the humanities
Security and space
Euratom: Fusion energy research, nuclear fission and radiation protection +

8. Collaborative Research changing priorities (relative weight)
FP1
FP2
FP3
FP4
FP5
FP6
Socio -economic
Transport
Environment
Industrial + materials tech.
ICT
Energy
Life Sciences*
FP7
Security + Space
*from FP6 split into: Health + Food/Agri/Biotech

9. Health Research Objectives: Improving the health of European citizens
Increasing the competitiveness of European health-related industries and business
Addressing global health issues including emerging epidemics

10. + Health Research Rationale for pan-European approach (I):
Sequencing of human genome advances in post-genomics vast amount of data, accelerated discovery
Translational research multidisciplinary
Health policy-driven research comparisons of national models & data +
Rationale for pan-EU approaches (I):
Sequencing of human genome and recent advances in post-genomics  vast amounts of data
Translational research (translation of basic discoveries in clinical applications)  multidisciplinarity
Health policy-driven research  comparisons of the national models & data

11. Health Research Rationale for pan-European approach (II):
Strong EU-based biomedical research strengthen the competitiveness of large industries (pharma) and SMEs (healthcare biotech & medical technology)
Transnational co-operation is essential to face the worldwide competition
Contribute to the development of norms & standards to set up appropriate legislative framework for new medical technologies (e.g. regenerative medicine)

12. 1. Health Three pillars of activities:
Budget:
€6 billion over 7 years ( )
Three pillars of activities:
Biotechnology, generic tools and technologies for human health
Translating research for human health
Optimising the delivery of healthcare to European citizens

13. Collaborative research in Health
1: Biotechnology, generic tools and technologies
High-throughput research (enhancing data generation, standardisation, acquisition & analysis)
Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches)
Innovative therapeutic approaches and interventions (with potential application in many diseases and disorders)
Predicting suitability, safety and efficacy of therapies (biological markers, in vivo and in vitro methods and models, simulation, pharmacogenomics, targeting etc.)

14. Collaborative research in Health
2: Translating research for human health
Integrating biological data and processes: (large-scale data gathering, systems biology)
Research on the brain and neurological diseases, human development and ageing
Infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics, NID)
Other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)

15. Collaborative research in Health
3: Optimising the delivery of health care
Enhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health etc.)
Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking etc.)
Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems etc.)

16. European Technology Platform The Innovative Medicines Initiative

17. Creating new medicines is a high risk journey15 10 5
Idea
Medicine
years
The problem is global and very complex
The situation is unsustainable
We need new creative approaches
Some initiatives has been presented here today

18. The Innovative Medicines Initiative
Starting point:
drug development: increasing cost, duration and risk
competitiveness of pharmaceutical industry affected
EU concerned by loss of leadership in pharma R&D
Response: the Innovative Medicines Initiative
collaborative effort between EC and pharmaceutical industry (EFPIA)
tackle specific issues where research is the key
Public Private Partnership for implementation

19. Calls for proposals in 2007 Health theme
First calls for proposals issued 22 Dec.’06
first deadline: 19 April €628 million
second deadline: 18 September €532 million1
[ not all areas will be open in each call ]
1: pending approval of 2008 budget

20. Evaluation Peer review by invited experts Criteria:
S+T quality -of the concept, objectives and methodology
Impact -potential impact, dissemination, exploitation, use
Implementation -management, quality of consortium, resources

21. International Collaboration -issues at stake:
Development assistance policy objectives, e.g. Millennium Development Goals targets: poor countries, e.g. ACP
Strengthening EU competitiveness competing with industrialised countries (e.g. attracting excellence) collaboration for mutual gains targets: more developed countries (e.g. BRIC)
Science diplomacy collaborating w. industrialised countries “ice breaking” when collaborating w. new partner countries putting “meat on the bones” of S+T agreements a sign of maturity of the FPs (openness) targets: OECD, all 3rd countries

22. International Collaboration -what is new in FP7?
The management of thematic INCO projects moves from the INCO directorate to the thematic directorates
 INCO-Health to Health Research
-better synergies with traditional collaborative projects in the theme
-greater visibility for INCO projects as part of a larger portfolio

23. International Collaboration in FP7
2 different avenues:
1. All activities open for International Cooperation
International Cooperation Partner Countries (ICPCs) can participate in projects and receive EC funding
Minimum number of participants: 3 from MS/AS
2. Specific International Cooperation Actions
Address specific issues of partner countries or with a global character, on the basis of mutual interest and benefit
Minimum number of participants: (2 from MS/AS + 2 from ICPCs)

24. International Collaboration in FP7 Health
Example of a SICA topics in the first Work Programme (deadlines in 2007)
Childhood and adolescent mental disorders The research should be aimed at investigating paediatric mental disorders that have a high prevalence in countries of Central and Eastern Europe. The projects should use population genetics/genomics approaches and include bioinformatics/biostatistics to increase knowledge of the patterns of disease prevalence and develop possible diagnostic and therapeutic strategies as well as address prevention.

25. International Collaboration in FP7 Health
Example of a SICA topics in the first Work Programme (deadlines in 2007)
Epidemiological investigations into long-term trends of population health as consequence of socio-economic transitions, including life-style induced health problems Investigations into tackling the burden of chronic diseases such as diabetes, cardiovascular and liver diseases, for identifying strategies at the population level to implement effective solutions to improve health. Specific International Cooperation Action. Targeted regions: Mediterranean Partner countries, Russia, Eastern European and Central Asia.

26. International Collaboration in FP7 Health
Other initiatives
International activities in large scale data gathering for functional genomics
-organising and coordinating endeavours aiming at collecting, integrating and curating genomics, proteomics, population genetics, comparative and functional genomics data and/or samples of relevance to human health

27. Collaborative Health research in FP7
SUMMARY
Continuity in collaborative Health research to:
develop new tools and technologies
promote translational research
optimise delivery of health care
[ using usual FP funding mechanisms ]
&
A novel approach to improve drug development:
The Innovative Medicines Initiative
[ using the proposed Joint Technology Initiative in FP7 ]

29. Information EU research: http://ec.europa.eu/research
Seventh Framework Programme:
Information on research programmes and projects:
RTD info magazine:
Information requests: